ATA112089A - Harzadsorbat ranitidinpräparate und verfahren zu ihrer herstellung - Google Patents

Harzadsorbat ranitidinpräparate und verfahren zu ihrer herstellung

Info

Publication number
ATA112089A
ATA112089A AT0112089A AT112089A ATA112089A AT A112089 A ATA112089 A AT A112089A AT 0112089 A AT0112089 A AT 0112089A AT 112089 A AT112089 A AT 112089A AT A112089 A ATA112089 A AT A112089A
Authority
AT
Austria
Prior art keywords
ranitidine
preparations
production
resin adsorbate
adsorbate
Prior art date
Application number
AT0112089A
Other languages
English (en)
Other versions
AT401614B (de
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888811167A external-priority patent/GB8811167D0/en
Priority claimed from GB888816185A external-priority patent/GB8816185D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ATA112089A publication Critical patent/ATA112089A/de
Application granted granted Critical
Publication of AT401614B publication Critical patent/AT401614B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
AT0112089A 1988-05-11 1989-05-10 Harzadsorbat ranitidinpräparate und verfahren zu ihrer herstellung AT401614B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888811167A GB8811167D0 (en) 1988-05-11 1988-05-11 Medicaments
GB888816185A GB8816185D0 (en) 1988-07-07 1988-07-07 Medicaments

Publications (2)

Publication Number Publication Date
ATA112089A true ATA112089A (de) 1996-03-15
AT401614B AT401614B (de) 1996-10-25

Family

ID=26293879

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0112089A AT401614B (de) 1988-05-11 1989-05-10 Harzadsorbat ranitidinpräparate und verfahren zu ihrer herstellung

Country Status (35)

Country Link
US (1) US5032393A (de)
JP (1) JP2944678B2 (de)
KR (1) KR890016968A (de)
CN (1) CN1027133C (de)
AT (1) AT401614B (de)
AU (1) AU624613B2 (de)
BE (1) BE1002159A5 (de)
CA (1) CA1337272C (de)
CH (1) CH679011A5 (de)
CY (1) CY1781A (de)
DE (1) DE3915347C2 (de)
DK (1) DK168934B1 (de)
ES (1) ES2011573A6 (de)
FI (1) FI92060C (de)
FR (1) FR2631232B1 (de)
GB (1) GB2218333B (de)
GR (1) GR1000358B (de)
HK (1) HK45094A (de)
HU (2) HU204994B (de)
IE (1) IE60722B1 (de)
IL (1) IL90245A (de)
IT (1) IT1232831B (de)
LU (1) LU87515A1 (de)
MX (1) MX173349B (de)
MY (1) MY104013A (de)
NL (1) NL8901188A (de)
NO (1) NO175131C (de)
NZ (1) NZ229064A (de)
PH (1) PH27612A (de)
PL (1) PL279377A1 (de)
PT (1) PT90523B (de)
RU (1) RU2033155C1 (de)
SE (1) SE508343C2 (de)
SG (1) SG48194G (de)
YU (1) YU47674B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
SE9003902D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Solid dosage forms of a drug
GB8925484D0 (en) * 1989-11-10 1989-12-28 Glaxo Group Ltd Process
AU8546591A (en) * 1990-09-13 1992-04-15 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
SE9003903D0 (sv) * 1990-12-07 1990-12-07 Astra Ab New pharmaceutical formulations
JPH06504059A (ja) * 1990-12-21 1994-05-12 リチャードソン、ビックス、インコーポレーテッド ポリアミン薬物−樹脂複合体
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
JP3207494B2 (ja) * 1992-04-02 2001-09-10 ロート製薬株式会社 水性懸濁製剤
JP3278192B2 (ja) * 1992-04-03 2002-04-30 ロート製薬株式会社 徐放性液剤
GB9211148D0 (en) * 1992-05-26 1992-07-08 Smithkline Beecham Plc Novel treatment
GB9221414D0 (en) * 1992-10-13 1992-11-25 Glaxo Group Ltd Pharmaceutical compositions
WO1994008576A1 (en) * 1992-10-16 1994-04-28 Glaxo Group Limited Taste-masking compositions of ranitidine
EP0620001A1 (de) * 1993-04-16 1994-10-19 McNEIL-PPC, INC. Wässrige pharmazeutische Suspension und Verfahren zu ihrer Herstellung
GB9324409D0 (en) * 1993-11-27 1994-01-12 Smithkline Beecham Plc Novel composition
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
JP4283355B2 (ja) * 1997-11-10 2009-06-24 久光製薬株式会社 薬剤用徐放化剤及びそれを含有した徐放性医薬組成物
CA2309597A1 (en) 1997-11-10 1999-05-20 Hiroshi Sorimachi Sustainedly releasing agents for medicines and sustainedly released medicinal compositions containing the same
ATE411047T1 (de) * 1999-07-14 2008-10-15 Schering Plough Ltd Maskieren des geschmacks der oralen flüssigen chinolon-zubereitungen mit ionenaustauscherharzen
US6514492B1 (en) 1999-07-14 2003-02-04 Schering-Plough Veterinary Corporation Taste masking of oral quinolone liquid preparations using ion exchange resins
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US20020031490A1 (en) * 2000-07-27 2002-03-14 Bellamy Simon Andrew Method for preparing resinates
EP1429728A1 (de) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Zubereitungen mit verzögerter freisetzung
ATE396746T1 (de) * 2002-01-18 2008-06-15 Rohm & Haas Verwendung eines resinats zur herstellung einer formulierung zur beendigung des rauchens
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050142097A1 (en) * 2003-12-29 2005-06-30 Deepak Thassu Multiple active drug resin conjugate
WO2007001300A1 (en) * 2005-06-28 2007-01-04 Ucb, S.A. Multiple active drug-resin conjugate
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
EP1926736A4 (de) * 2005-09-21 2010-08-25 Chong Kun Dang Pharm Corp Neuer resinat-komplex von s-clopidogrel und verfahren zu dessen herstellung
EP2018160B1 (de) 2006-03-16 2011-12-14 Tris Pharma, Inc. Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
CN100411626C (zh) * 2006-08-28 2008-08-20 浙江大学 缓释型碘补充剂的制备方法
US8287848B2 (en) 2006-10-03 2012-10-16 Tris Pharma Inc Formulations containing an ionic mineral-ion exchange resin complex and uses thereof
CN100450548C (zh) * 2006-12-22 2009-01-14 江苏奥赛康药业有限公司 一种波拉克林树脂组合物的口腔贴片及其制备方法
MX2010003928A (es) * 2007-10-11 2010-09-10 Philip Morris Prod Producto de tabaco sin humo.
WO2009102830A1 (en) * 2008-02-13 2009-08-20 Eurand Inc Orally disintegrating tablet compositions of ranitidine and methods of manufacture
JP5560701B2 (ja) * 2008-12-26 2014-07-30 ライオン株式会社 ラニチジン含有医薬固形製剤及びラニチジン担持粒子の製造方法
JP5412966B2 (ja) * 2009-06-08 2014-02-12 ライオン株式会社 粒状製剤
US8357398B2 (en) * 2009-10-21 2013-01-22 Alitair Pharmaceuticals Inc. Benzonatate compositions and methods of use
CN102198118B (zh) * 2011-03-28 2012-08-29 于晓勇 一种治疗呕吐的口腔药物制剂及其制备方法
CN102138915A (zh) * 2011-03-28 2011-08-03 于晓勇 一种口服药物制剂及其制备方法
BR112015003120B1 (pt) 2012-08-15 2022-08-09 Tris Pharma , Inc Tablete mastigável de liberação estendida de metilfenidato e seu uso
RU2761346C2 (ru) * 2016-11-01 2021-12-07 Джонсон энд Джонсон Консьюмер Инк. Жидкая пероральная фармацевтическая лекарственная форма, содержащая антагонист h2-рецептора гистамина и антацид
EP3784214A4 (de) 2018-04-27 2022-01-19 Johnson & Johnson Consumer Inc. Flüssige orale pharmazeutische darreichungsform

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR803638A (fr) * 1935-06-21 1936-10-05 Système de freinage pour portes coulissantes
US2828207A (en) * 1955-11-14 1958-03-25 Du Pont Fortification of feed
US2990332A (en) * 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US2970053A (en) * 1958-10-28 1961-01-31 Pfizer & Co C Oleandomycin resin adsorbate
US3138525A (en) * 1961-06-16 1964-06-23 Hoffmann La Roche Castor wax-amprotropine-resin compositions
US3949068A (en) * 1964-02-20 1976-04-06 University Of Alabama In Birmingham Medical And Educational Foundation Pharmaceutical compositions
GB1180233A (en) * 1966-02-23 1970-02-04 Jean Astruc Modified Spiramycin
US3624209A (en) * 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
GB1218102A (en) * 1968-03-15 1971-01-06 Philips Nv Improvements in medicaments comprising drug/ion-exchange resin compounds
JPS5146154B2 (de) * 1972-05-11 1976-12-07
GB1462356A (en) * 1973-07-10 1977-01-26 Beecham Group Ltd Pharmaceutical compositions
JPS51125708A (en) * 1974-07-23 1976-11-02 Beecham Group Ltd Production of betaalactam antibiotic complex
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
CY1306A (en) * 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
EP0077529B1 (de) * 1981-10-16 1985-07-17 Sanol Schwarz GmbH Arzneimittelformulierung
GB8313217D0 (en) * 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
NZ215069A (en) * 1985-03-01 1988-06-30 Reckitt & Colmann Prod Ltd Pharmaceutical composition with histamine h 2 -receptor antagonist
US4788055A (en) * 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
JPS6369038A (ja) * 1986-09-10 1988-03-29 Canon Inc 光カ−ド記録媒体
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents

Also Published As

Publication number Publication date
FI892248A0 (fi) 1989-05-10
NO891906D0 (no) 1989-05-10
NZ229064A (en) 1991-12-23
NO175131C (no) 1994-09-07
IT1232831B (it) 1992-03-05
SE8901671D0 (sv) 1989-05-10
IL90245A (en) 1994-04-12
PT90523B (pt) 1994-10-31
HK45094A (en) 1994-05-13
DE3915347A1 (de) 1989-11-16
IL90245A0 (en) 1989-12-15
YU97189A (en) 1990-06-30
FI92060B (fi) 1994-06-15
CN1027133C (zh) 1994-12-28
DK168934B1 (da) 1994-07-11
CH679011A5 (de) 1991-12-13
SE8901671L (sv) 1989-11-12
ES2011573A6 (es) 1990-01-16
FI92060C (fi) 1994-09-26
GB2218333A (en) 1989-11-15
HUT50036A (en) 1989-12-28
KR890016968A (ko) 1989-12-14
US5032393A (en) 1991-07-16
CY1781A (en) 1995-10-20
PT90523A (pt) 1989-11-30
AU3461789A (en) 1989-11-16
RU2033155C1 (ru) 1995-04-20
IE60722B1 (en) 1994-08-10
CN1037651A (zh) 1989-12-06
GB2218333B (en) 1991-11-06
BE1002159A5 (fr) 1990-08-14
SG48194G (en) 1994-11-25
MX15983A (es) 1993-10-01
AT401614B (de) 1996-10-25
DK229489A (da) 1989-11-12
FR2631232B1 (fr) 1993-11-19
AU624613B2 (en) 1992-06-18
GR1000358B (el) 1992-06-30
MX173349B (es) 1994-01-22
SE508343C2 (sv) 1998-09-28
JP2944678B2 (ja) 1999-09-06
PH27612A (en) 1993-08-31
YU47674B (sh) 1996-01-08
NO891906L (no) 1989-11-13
NL8901188A (nl) 1989-12-01
PL279377A1 (en) 1990-01-22
IT8947938A0 (it) 1989-05-10
GR890100314A (en) 1990-03-12
GB8910706D0 (en) 1989-06-28
IE891527L (en) 1989-11-11
DK229489D0 (da) 1989-05-10
CA1337272C (en) 1995-10-10
FR2631232A1 (fr) 1989-11-17
LU87515A1 (fr) 1990-06-12
HU211592A9 (en) 1995-12-28
DE3915347C2 (de) 1994-11-03
FI892248A (fi) 1989-11-12
HU204994B (en) 1992-03-30
NO175131B (no) 1994-05-30
JPH02111719A (ja) 1990-04-24
MY104013A (en) 1993-10-30

Similar Documents

Publication Publication Date Title
ATA112089A (de) Harzadsorbat ranitidinpräparate und verfahren zu ihrer herstellung
DE3682874D1 (de) Pyranoindolizinderivate und verfahren zu ihrer herstellung.
ATA125988A (de) Pharmazeutische cefuroximaxetil-zusammensetzung und verfahren zu ihrer herstellung
ATA176789A (de) Intravenös anwendbare pharmazeutische präparate und verfahren zu ihrer herstellung
DE68904712T2 (de) Bienenwabenstruktur und verfahren zu ihrer herstellung.
DE3782994D1 (de) Erythromycin-a-derivate und verfahren zu ihrer herstellung.
DE68908061D1 (de) Verpackte batterien und verfahren zu ihrer herstellung.
DE3878475D1 (de) Organopolysiloxanemulsion und verfahren zu ihrer herstellung.
DE3873086D1 (de) Plattenartig geformter katalysator und verfahren zu dessen herstellung.
ATA247489A (de) Festes pharmazeutisches piroxicam-präparat und verfahren zu seiner herstellung
DE68927880T2 (de) Verzweigte polycarbonate und verfahren zu ihrer herstellung
DE68923993T2 (de) Polymaleimid-Verbindungen und Verfahren zu ihrer Herstellung.
DE3685013D1 (de) Amino-trifluormethylpyridinverbindung und verfahren zu ihrer herstellung.
PT81713A (de) Oeladjuvierte vaccine und verfahren zu ihrer herstellung
DE3677259D1 (de) Chinazolinonverbindungen und verfahren zu ihrer herstellung.
AT399879B (de) Dihydro-pyrimido-thiazin-derivate und verfahren zu ihrer herstellung
DE3777245D1 (de) Protein und verfahren zu dessen herstellung.
DE3672931D1 (de) Chinoloncarbonsaeurederivate und verfahren zu ihrer herstellung.
DE3674733D1 (de) Vernetzbare polycyclische polycarbonatoligomere und verfahren zu ihrer herstellung.
DE68914500T2 (de) Alkylarylsulfone und Verfahren zu ihrer Herstellung.
DE68903581T2 (de) In der landwirtschaft verwendbare substanz und verfahren zu ihrer herstellung.
DE3765239D1 (de) Acetylketendialkylacetale und verfahren zu ihrer herstellung.
DE3867392D1 (de) Phenoxyalkancarbonsaeurederivate und verfahren zu ihrer herstellung.
DE3688287T2 (de) Spirodiphosphoamidatverbindungen und verfahren zu ihrer herstellung.
DE3678018D1 (de) 5-thiaprostaglandine-e1 und verfahren zu ihrer herstellung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
ELJ Ceased due to non-payment of the annual fee